Hikma Pharmaceuticals Valuation

Is H5P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of H5P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: H5P (€22.4) is trading below our estimate of fair value (€47.74)

Significantly Below Fair Value: H5P is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for H5P?

Other financial metrics that can be useful for relative valuation.

H5P key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.1x
Enterprise Value/EBITDA7.6x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does H5P's PE Ratio compare to its peers?

The above table shows the PE ratio for H5P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.8x
DMP Dermapharm Holding
20.1x20.0%€1.7b
MRK Merck KGaA
25.4x10.7%€66.8b
PSG PharmaSGP Holding
15.8x14.6%€287.8m
2FJ0 Pierrel
29.9xn/a€92.8m
H5P Hikma Pharmaceuticals
18.7x12.7%€4.1b

Price-To-Earnings vs Peers: H5P is good value based on its Price-To-Earnings Ratio (18.7x) compared to the peer average (22.8x).


Price to Earnings Ratio vs Industry

How does H5P's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: H5P is good value based on its Price-To-Earnings Ratio (18.7x) compared to the European Pharmaceuticals industry average (21.4x).


Price to Earnings Ratio vs Fair Ratio

What is H5P's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

H5P PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18.9x
Fair PE Ratio17.2x

Price-To-Earnings vs Fair Ratio: H5P is expensive based on its Price-To-Earnings Ratio (18.7x) compared to the estimated Fair Price-To-Earnings Ratio (17.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst H5P forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€22.40
€27.57
+23.1%
8.7%€32.41€23.48n/a10
Oct ’25€23.00
€27.21
+18.3%
10.7%€33.14€22.80n/a11
Sep ’25€23.80
€27.19
+14.3%
11.6%€33.70€23.19n/a11
Aug ’25€22.40
€26.50
+18.3%
13.2%€33.10€21.88n/a11
Jul ’25€22.20
€27.03
+21.8%
13.4%€33.82€22.35n/a11
Jun ’25€22.40
€26.67
+19.1%
13.3%€32.85€21.92n/a11
May ’25€22.60
€26.73
+18.3%
13.3%€32.95€21.91n/a11
Apr ’25€22.60
€26.87
+18.9%
12.6%€32.52€21.87n/a11
Mar ’25€22.80
€26.49
+16.2%
12.1%€32.16€21.76n/a11
Feb ’25€22.20
€25.69
+15.7%
12.3%€30.81€21.64n/a11
Jan ’25€20.40
€25.38
+24.4%
12.1%€30.43€21.38n/a11
Dec ’24€20.40
€26.34
+29.1%
11.8%€31.29€21.97n/a11
Nov ’24€22.00
€27.36
+24.4%
10.6%€33.13€22.98€22.4011
Oct ’24€24.20
€27.74
+14.6%
10.5%€33.11€22.97€23.0011
Sep ’24€25.20
€26.42
+4.8%
11.5%€32.02€21.54€23.8012
Aug ’24€24.60
€24.17
-1.7%
13.1%€31.25€19.84€22.4012
Jul ’24€22.00
€24.30
+10.5%
14.0%€31.68€19.55€22.2012
Jun ’24€21.00
€24.00
+14.3%
14.9%€32.00€19.74€22.4011
May ’24€21.20
€23.02
+8.6%
15.8%€31.51€19.07€22.6011
Apr ’24€19.00
€23.20
+22.1%
15.1%€31.15€19.13€22.6011
Mar ’24€19.70
€22.84
+15.9%
15.1%€31.01€19.05€22.8012
Feb ’24€19.30
€22.15
+14.8%
17.4%€30.99€16.23€22.2012
Jan ’24€17.40
€21.84
+25.5%
21.3%€31.97€14.82€20.4012
Dec ’23€17.70
€22.53
+27.3%
24.9%€31.99€14.83€20.4011
Nov ’23€15.10
€24.67
+63.4%
23.8%€34.69€15.58€22.0011

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies